Zymeworks(US:ZYME) ZACKS·2026-03-02 13:15分组1 - Zymeworks Inc. reported a quarterly loss of $0.55 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.35, marking an earnings surprise of -58.64% [1] - The company posted revenues of $2.52 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 88.23%, compared to revenues of $31.03 million a year ago [2] - Zymeworks shares have declined approximately 11.6% since the beginning of the year, while the S&P 500 has gained 0.5% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.21 on revenues of $57.98 million, and for the current fiscal year, it is $0.65 on revenues of $267.81 million [7] - The Medical - Biomedical and Genetics industry, to which Zymeworks belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]